Novartis Extends RNAi Deal With Alnylam
This article was originally published in The Pink Sheet Daily
Executive Summary
Terms include another year and potential for more equity.
You may also be interested in...
Renamed Nastech Turns To RNAi
Company to divest intranasal program rather than spin out.
Alnylam’s Anti-Viral RNAi Drug Shown Effective In Humans
Phase II “de-risking” trial shows infection-rate knockdown.
Back in Fashion: Discovery Platforms (Certain Kinds, at Least)
After the millennial boom in genome-related financings, platform companies went into hiding, surfacing again a few years later in product costume. But much of that has changed. Platforms are getting fed again-largely because, one step higher on the food chain, buyers have an appetite for them.